Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis
Publication

Publications

Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis

Title
Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis
Type
Article in International Scientific Journal
Year
2021
Authors
Ferreira, JP
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Oliveira, AC
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Saraiva, FA
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Vasques Novoa, F
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Leite-Moreira AF
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 184
Pages: 783-790
ISSN: 0804-4643
Publisher: BioScientifica Ltd.
Other information
Authenticus ID: P-00T-WK1
Abstract (EN): Background: Patients with insulin-treated type 2 diabetes (T2D) have a high risk of major adverse cardiovascular events. Sodium-glucose cotransporter inhibitors (SGLTi) improve outcomes without hypoglycaemic risk. Aims: To study the effect of SGLTi in patients with T2D with and without background insulin treatment in outcome-driven RCTs. Methods: Random effects models. Results: A total of 54 374 patients with T2D were included in the analysis, of which 26 551 (48.8%) were treated with insulin. For 3P-MACE in patients without insulin treatment, the HR (95% CI) for the effect of SGLTi vs placebo was 0.93 (0.81-1.05), with moderate heterogeneity (I-2 = 49.2%, Q statistic P = 0.11). In insulin-treated patients, the HR (95% CI) was 0.88 (0.82-0.95), without evidence of heterogeneity (I-2 =0.0%, Q statistic P =0.91). The pooled effect evidenced a 10% reduction of 3P-MACE with SGLTi (HR: 0.90, 95% CI: 0.85-0.96), without SGLTi-by-insulin interaction P = 0.53. For the composite outcome of HF hospitalisation or cardiovascular death in patients without insulin treatment, the HR (95% CI) for the effect of SGLTi vs placebo was 0.77 (0.61-0.92), with marked heterogeneity (I-2 = 66.8%, Q statistic P = 0.02). In insulin- treated patients, the HR (95% CI) was 0.77 (0.68-0.86), without significant heterogeneity (I-2 = 31.7%, Q statistic P = 0.25). The pooled effect evidenced a 23% reduction of HF hospitalisations or cardiovascular death with SGLTi (HR: 0.77, 95% CI: 0.68-0.85), without SGLTi-by-insulin interaction P = 0.98. Conclusion: SGLTi reduces cardiovascular events regardless of insulin use. However, the treatment effect is more homogeneous among insulin-treated patients, supporting the use of SGLTi for the treatment of patients with T2D requiring insulin for glycaemic control.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 8
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Clinical and Pathophysiologic Insights of Free triiodothyronine/Free thyroxine Ratio in Patients with Heart Failure with Preserved Ejection Fraction: Data from the NETDiamond Cohort (2023)
Another Publication in an International Scientific Journal
Leite, AR; Neves, JS; Angélico Gonçalves, A; Vasques Nóvoa, F; Saraiva, FA; Pinho, IB; Oliveira, AC; Borges Canha, M; von Hafe, M; Vale, C; Andre P Lourenco; Filipe Macedo; Araújo JP; von Hafe P; Almeida, J; Ferreira, JP; Leite-Moreira AF

Of the same journal

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis (2020)
Another Publication in an International Scientific Journal
van Hulsteijn, LT; Pasquali, R; Casanueva, F; Haluzik, M; Ledoux, S; Monteiro, M; Salvador, J; Santini, F; Toplak, H; Dekkers, OM
Non-invasive follicular thyroid neoplasm with papillary-like nuclear feature: clinical, pathological, and molecular update 5 years after the nomenclature revision (2023)
Another Publication in an International Scientific Journal
Melo, M; Ventura, M; Cardoso, L; da Rocha, AG; Paiva, I; Sobrinho-Simoes, M; Soares, P
ENDOCRINE TUMOURS Genetic predictors of thyroid cancer outcome (2016)
Another Publication in an International Scientific Journal
Tavares, C; Melo, M; Manuel Cameselle Teijeiro, JM; Soares, P; Sobrinho Simoes, M
Diagnostic tests for Cushing's syndrome differ from published guidelines: Data from ERCUSYN (2017)
Another Publication in an International Scientific Journal
Valassi, E; Franz, H; Brue, T; Feelders, RA; Netea Maier, R; Tsagarakis, S; Webb, SM; Yaneva, M; Reincke, M; Droste, M; Komerdus, I; Maiter, D; Kastelan, D; Chanson, P; Pfeifer, M; Strasburger, CJ; Tóth, M; Chabre, O; Tabarin, A; Krsek, M...(mais 76 authors)
Cell cycle regulation in adrenocortical carcinoma (2018)
Another Publication in an International Scientific Journal
Pereira, SS; Monteiro, M; Bourdeau, I; Lacroix, A; Pignatelli, D

See all (22)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-07 at 18:19:37 | Privacy Policy | Personal Data Protection Policy | Whistleblowing